Rahul Banerjee, MD, assistant professor, Clinical Research Division, University of Washington Fred Hutchinson Cancer Center, Seattle, Washington, discusses the challenges facing CAR T-cell therapy in multiple myeloma. Dr Banerjee notes that access to CAR T-cell therapy and the lengthy timeline for manufacturing may impact patient care.
Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from a recent study of real-world…
In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL,…
Michael Wang, MD, professor, Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from the TRANSCEND-NHL-001 study, which was designed to investigate…
Adriana Rossi, MD, assistant professor of medicine, director of CART and the Stem Cell Transplant Clinical Service at the Center of Excellence for Multiple Myeloma, Mount Sinai, New…
Patrick Connor Johnson, MD, Massachusetts General Hospital, Boston, Massachusetts, discusses real-world outcomes following treatment with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Dr Johnson notes the…
Manali Kamdar, MD, clinical director of lymphoma services, University of Colorado Cancer Center, Denver, Colorado, discusses the use of circulating tumor DNA as an early predictor of outcomes…
Tara K. Gregory, MD, Colorado Blood Cancer Institute, Denver, Colorado, discusses CAR T-cell therapy for multiple myeloma. Dr Gregory reviews steps involved in CAR T-cell therapy, potential outcomes…
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses findings from one arm of the Phase 2 KarMMA-2 trial that was designed to investigate idecabtagene vicleucel in…
Multiple Myeloma is a cancer that affects plasma cells in bone marrow. Abnormal plasma cells produce harmful proteins, leading to anemia, bone pain, frequent infections, and kidney failure.…
Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…